These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28969591)

  • 1. Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study.
    Ankrah DNA; Lartey M; Mantel-Teeuwisse AK; Leufkens HGM
    BMC Infect Dis; 2017 Oct; 17(1):664. PubMed ID: 28969591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
    Birlie B; Braekers R; Awoke T; Kasim A; Shkedy Z
    BMC Infect Dis; 2017 Jun; 17(1):453. PubMed ID: 28655306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study.
    Ayele T; Jarso H; Mamo G
    AIDS Res Ther; 2017 Feb; 14(1):5. PubMed ID: 28143541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
    Velen K; Lewis JJ; Charalambous S; Grant AD; Churchyard GJ; Hoffmann CJ
    PLoS One; 2013; 8(5):e64459. PubMed ID: 23691224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
    Li T; Guo F; Li Y; Zhang C; Han Y; Lye W; He Y; Lu H; Xie J; Huang A; Li Y; Tang X; Wang H; Zhang T; Gao G; Lei J; Zhang X; Wu X; Sun Y; Bai J; Luo L; Wang H
    Chin Med J (Engl); 2014; 127(1):59-65. PubMed ID: 24384425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
    HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting.
    Kumarasamy N; Venkatesh KK; Devaleenol B; Saghayam S; Manohar D; Poongulali S; Yepthomi T; Ambrose P; Solomon S; Mayer KH
    Int J Infect Dis; 2009 Nov; 13(6):e360-4. PubMed ID: 19328734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana.
    Tetteh RA; Nartey ET; Lartey M; Mantel-Teeuwisse AK; Leufkens HG; Nortey PA; Dodoo AN
    BMC Public Health; 2015 Jun; 15():573. PubMed ID: 26092496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
    Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P;
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
    ; Ratsela A; Polis M; Dhlomo S; Emery S; Grandits G; Khabo P; Khanyile T; Komati S; Neaton JD; Naidoo LC; Magongoa D; Qolohle D
    J Infect Dis; 2010 Nov; 202(10):1529-37. PubMed ID: 20942650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
    Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
    Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N
    Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs.
    Zhou F; Kominski GF; Qian HZ; Wang J; Duan S; Guo Z; Zhao X
    BMC Med; 2011 Jan; 9():6. PubMed ID: 21241494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.
    Kumarasamy N; Vallabhaneni S; Cecelia AJ; Yepthomi T; Balakrishnan P; Saghayam S; Flanigan TP; Carpenter CC; Solomon S; Mayer KH
    J Acquir Immune Defic Syndr; 2006 Jan; 41(1):53-8. PubMed ID: 16340473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial.
    Venter WDF; Kambugu A; Chersich MF; Becker S; Hill A; Arulappan N; Moorhouse M; Majam M; Akpomiemie G; Sokhela S; Poongulali S; Feldman C; Duncombe C; Ripin DHB; Vos A; Kumarasamy N
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):224-233. PubMed ID: 30640204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic antiretroviral drug use in HIV-infected patients: A cohort study from the French health insurance database.
    Rwagitinywa J; Lapeyre-Mestre M; Bourrel R; Sommet A
    Therapie; 2018; 73(3):257-266. PubMed ID: 29195713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies.
    Antiretroviral Therapy Cohort Collaboration
    J Infect Dis; 2006 Sep; 194(5):612-22. PubMed ID: 16897660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?
    Brennan AT; Davies MA; Bor J; Wandeler G; Stinson K; Wood R; Prozesky H; Tanser F; Fatti G; Boulle A; Sikazwe I; Wool-Kaloustian K; Yuannoutsos C; Leroy V; de Rekeneire N; Fox MP
    AIDS; 2017 Jan; 31(1):147-157. PubMed ID: 27776039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line therapy and mitochondrial damage: different nucleosides, different findings.
    Blanco F; García-Benayas T; José de la Cruz J; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(1):11-9. PubMed ID: 12577192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.